PL376052A1 - Peptydy terapeutyczne - Google Patents

Peptydy terapeutyczne

Info

Publication number: PL376052A1
Authority: PL; Poland
Prior art keywords: ligand; provides; therapeutic peptides; product; sulphonation
Prior art date: 2002-10-02

Application number

PL03376052A

Other languages

English (en)

Inventor

Mumtaz Virji

Original Assignee

University Of Bristol

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-02

Filing date

2003-10-01

Publication date

2005-12-12

2003-10-01 Application filed by University Of Bristol filed Critical University Of Bristol

2005-12-12 Publication of PL376052A1 publication Critical patent/PL376052A1/pl

Links

230000001225 therapeutic effect Effects 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
239000003446 ligand Substances 0.000 abstract 3
102000005962 receptors Human genes 0.000 abstract 2
108020003175 receptors Proteins 0.000 abstract 2
241000588655 Moraxella catarrhalis Species 0.000 abstract 1
101710116435 Outer membrane protein Proteins 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
230000013595 glycosylation Effects 0.000 abstract 1
238000006206 glycosylation reaction Methods 0.000 abstract 1
230000033444 hydroxylation Effects 0.000 abstract 1
238000005805 hydroxylation reaction Methods 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
238000012216 screening Methods 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
- C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Virology (AREA)
Biophysics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Immunology (AREA)
Toxicology (AREA)
Zoology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Detergent Compositions (AREA)

PL03376052A 2002-10-02 2003-10-01 Peptydy terapeutyczne PL376052A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0222764.3A GB0222764D0 (en)	2002-10-02	2002-10-02	Therapeutic peptide

Publications (1)

Publication Number	Publication Date
PL376052A1 true PL376052A1 (pl)	2005-12-12

Family

ID=9945111

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03376052A PL376052A1 (pl)	2002-10-02	2003-10-01	Peptydy terapeutyczne

Country Status (17)

Country	Link
EP (2)	EP2305700A1 (pl)
JP (1)	JP4763291B2 (pl)
KR (1)	KR101057587B1 (pl)
CN (1)	CN1305899C (pl)
AT (1)	ATE549348T1 (pl)
AU (1)	AU2003299131B2 (pl)
BR (1)	BR0315031A (pl)
CA (1)	CA2500960A1 (pl)
ES (1)	ES2383958T3 (pl)
GB (1)	GB0222764D0 (pl)
IL (1)	IL167780A (pl)
MX (1)	MXPA05003474A (pl)
NO (1)	NO20052108L (pl)
NZ (1)	NZ539575A (pl)
PL (1)	PL376052A1 (pl)
WO (1)	WO2004031236A2 (pl)
ZA (1)	ZA200503446B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1735446A2 (en) *	2004-04-15	2006-12-27	University Of Bristol	Therapeutic peptides
EA014352B1 (ru)	2005-08-10	2010-10-29	Арне Форсгрен Аб	Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента
TW201302779A (zh)	2011-04-13	2013-01-16	Glaxosmithkline Biolog Sa	融合蛋白質及組合疫苗

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0948625B1 (en) *	1996-12-20	2011-01-26	The Board Of Regents, The University Of Texas System	Uspa1 and uspa2 antigens of moraxella catarrhalis

2002
- 2002-10-02 GB GBGB0222764.3A patent/GB0222764D0/en not_active Ceased
2003
- 2003-10-01 WO PCT/GB2003/004273 patent/WO2004031236A2/en not_active Ceased
- 2003-10-01 AU AU2003299131A patent/AU2003299131B2/en not_active Ceased
- 2003-10-01 EP EP10177682A patent/EP2305700A1/en not_active Withdrawn
- 2003-10-01 KR KR1020057005764A patent/KR101057587B1/ko not_active Expired - Fee Related
- 2003-10-01 JP JP2004540969A patent/JP4763291B2/ja not_active Expired - Fee Related
- 2003-10-01 CA CA002500960A patent/CA2500960A1/en not_active Abandoned
- 2003-10-01 PL PL03376052A patent/PL376052A1/pl not_active IP Right Cessation
- 2003-10-01 MX MXPA05003474A patent/MXPA05003474A/es active IP Right Grant
- 2003-10-01 EP EP03756554A patent/EP1546194B1/en not_active Expired - Lifetime
- 2003-10-01 AT AT03756554T patent/ATE549348T1/de active
- 2003-10-01 CN CNB2003801017669A patent/CN1305899C/zh not_active Expired - Fee Related
- 2003-10-01 NZ NZ539575A patent/NZ539575A/en not_active IP Right Cessation
- 2003-10-01 ES ES03756554T patent/ES2383958T3/es not_active Expired - Lifetime
- 2003-10-01 BR BR0315031-3A patent/BR0315031A/pt not_active IP Right Cessation
2005
- 2005-03-31 IL IL167780A patent/IL167780A/en not_active IP Right Cessation
- 2005-04-29 ZA ZA200503446A patent/ZA200503446B/en unknown
- 2005-04-29 NO NO20052108A patent/NO20052108L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HK1076475A1 (en)	2006-01-20
CN1705678A (zh)	2005-12-07
CN1305899C (zh)	2007-03-21
ATE549348T1 (de)	2012-03-15
EP2305700A1 (en)	2011-04-06
AU2003299131B2 (en)	2010-04-22
IL167780A (en)	2011-05-31
AU2003299131A1 (en)	2004-04-23
EP1546194A2 (en)	2005-06-29
NZ539575A (en)	2006-06-30
KR101057587B1 (ko)	2011-08-19
WO2004031236A2 (en)	2004-04-15
BR0315031A (pt)	2005-08-16
NO20052108L (no)	2005-06-27
ES2383958T3 (es)	2012-06-27
MXPA05003474A (es)	2005-10-18
JP2006516952A (ja)	2006-07-13
CA2500960A1 (en)	2004-04-15
GB0222764D0 (en)	2002-11-06
JP4763291B2 (ja)	2011-08-31
ZA200503446B (en)	2006-10-25
EP1546194B1 (en)	2012-03-14
KR20050067410A (ko)	2005-07-01
WO2004031236A3 (en)	2004-06-24
NO20052108D0 (no)	2005-04-29

Similar Documents

Publication	Publication Date	Title
AU2003270643A1 (en)	2004-04-30	Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
PL392964A1 (pl)	2011-01-03	Antygen reaktywny wobec surowicy hiperimmunologicznej zastosowanie tego antygenu do produkcji preparatu farmaceutycznego, fragment hiperimmunologiczny antygenu, epitopy pomocnicze antygenu, szczepionka zawierająca antygen reaktywny wobec surowicy hiperimmunologicznej, preparat zawierający przeciwciała, sposób wytwarzania tego preparatu, zastosowanie preparatu do leczenia infekcji gronkowcowych oraz sposób przesiewania
DE69638022D1 (de)	2009-10-22	Aus wirbeltieren und darauf basierende verfahren
GR3034349T3 (en)	2000-12-29	Neutralizing monoclonal antibodies to respiratory syncytial virus
IS6455A (is)	2002-07-03	Stöðvun á vexti taugasíma fyrir milligöngu viðtaka Nogo
NL300830I2 (nl)	2020-08-31	Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten
EP1539228A4 (en)	2006-04-05	NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
SE0103754L (sv)	2002-10-06	Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
DK113389A (da)	1989-09-18	Monoklonale antistoffer
CN101405298A (zh)	2009-04-08	垂体腺苷酸环化酶激活肽(pacap)受体(vpac2)激动剂及其药物使用方法
DE69831007D1 (de)	2005-09-01	Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
DK0494294T3 (da)	1994-11-14	Bakterielle stressproteiner
PT996726E (pt)	2004-04-30	Proteina de membrana de celulas t (tirc7) peptidos e anticorpos dela derivados e suas utilizacoes
WO2005099337A3 (en)	2006-08-10	Therapeutic peptides
PL376052A1 (pl)	2005-12-12	Peptydy terapeutyczne
Rajnavölgyi et al.	1997	Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites
AU2003279352B2 (en)	2009-09-10	DNA sequence and recombinant production of the grass pollen allergen Phl p4
EP1467207A4 (en)	2006-06-07	Screening method
WO2003064446A3 (en)	2004-04-01	Plasma protein-binding peptides from bacterial curli
Khaddah et al.	2014	Assessment of preclinical efficacy antivenoms produced in rabbit by immunological methods and neutralization assays
Conde et al.	1975	Comparative studies of sheep immunoglobulins IgG1 and IgG2: Amino acid sequence of carboxy‐terminal cyanogen bromide fragments from their heavy chains
NO923749L (no)	1992-09-25	Bcrf1-antagonister for behandling av epstein-barr-virusinfeksjoner
WO2007042326A3 (en)	2007-08-02	Neisseria meningitidis antigens
HK1027837A (en)	2001-01-23	Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1)
WO2004005331A3 (en)	2004-06-10	Peptides derived from pep133 (g1p3, 6-16)

Legal Events

Date	Code	Title	Description
2013-08-30	VOID	Decisions declaring the decisions on the grant of the patent lapsed